About US
Contact us
-
Roche won't pursue Herceptin patents in IndiaRoche ($RHHBY) is throwing in the towel on its IP protection forHerceptininIndia. AsPharmAsia Newsreports, the company will give up its patents for Herceptin there, a move that opens it up to biosimil2013/8/19
-
South Africa's Adcock still in exclusive buyout talks with CFRSouth Africa's Adcock still in exclusive buyout talks with CFRSouth African drugmakerAdcock Ingramis so far staying true to suitorCFR Pharmaceuticals. Thursday, it said it remains in exclusive talks w2013/8/16
-
NY fund trustee to continue push for exec-pay clawbacks at AbbottNY fund trustee to continue push for exec-pay clawbacks at AbbottWhile other Big Pharma companies may have settled on clawback provisions for executive pay, hoping to inspire top management to toe the2013/8/16
-
China sales rep says Novartis ordered her to bribe doctorsChina sales rep says Novartis ordered her to bribe doctorsBig Pharma, beware of your former (and possibly current) employees inChina. Novartis ($NVS) is the latest drugmaker to be fingered forbriberyb2013/8/15
-
Boehringer sales tick upward 3% on big Pradaxa leapBoehringer sales tick upward 3% on big Pradaxa leapBoehringer Ingelheim's drugsPradaxaandTrajentaare both facing obstacles, but sales of both are still growing--and revenues for the company are growin2013/8/15
-
FDA: Infections prompt recall of all Specialty Compounding's sterile medsFDA: Infections prompt recall of all Specialty Compounding's sterile medsMore suspect drugs from a compounding pharmacy: The FDA says Specialty Compounding is yanking all of its sterile products after2013/8/14
-
Lawmakers demand Purdue Pharma's list of suspect OxyContin prescribersLawmakers demand Purdue Pharma's list of suspect OxyContin prescribers Now thatPurdue Pharmahas acknowledged news reports that it compiled a list of 1,800 doctors suspected of churning outOxyContin2013/8/14
-
Russia's Pharmstandard still weighing OTC unit sale, exec saysIn late June, Russia's Pharmstandard was reportedly considering a sale of itsOTCbusiness. A couple of weeks later, the company said it would spin the unit off instead. But the fate of that business is2013/8/13
-
Roche chief's comments about deal discipline push shares upHere's the latest example of parsing a pharma CEO's statements about M&A: After Roche ($RHHBY) chiefSeverin Schwansaid over the weekend that deals have to be "worth it financially," Notenstein ana2013/8/13
-
European Commission grants J&J, Celgene blood cancer approvalsTheEuropean Commissionwas good to blood cancer drugmakers this week, grantingmultiple myelomaapprovals for Johnson & Johnson's ($JNJ)Velcadeand Celgene's ($CELG)Imnovid. While Velcade was already2013/8/12